<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>As shown in a Spanish study, patients with rheumatoid arthritis (PAR) have a 4-fold increased risk of developing TB (tuberculosis) compared to the general population. Abruptly stopping anti-TNF (tumor necrosis factor α) agents after the development of TB could cause a paradoxical response leading to severe complications and death. We present the case of a 54 years old female patient with seropositive PAR since 2012 in treatment with biological therapy, which was diagnosed 10 years after the start of immunosuppressive treatment with miliary TB. She has had an unfavorable prognosis, dying after one month from the initiation of antituberculosis treatment due to septic shock. Therefore, it is very important to evaluate the bacillary status before initiating any immunosuppressive treatment.</p>
</abstract>

As shown in a Spanish study, patients with rheumatoid arthritis (PAR) have a 4-fold increased risk of developing TB (tuberculosis) compared to the general population. Abruptly stopping anti-TNF (tumor necrosis factor α) agents after the development of TB could cause a paradoxical response leading to severe complications and death. We present the case of a 54 years old female patient with seropositive PAR since 2012 in treatment with biological therapy, which was diagnosed 10 years after the start of immunosuppressive treatment with miliary TB. She has had an unfavorable prognosis, dying after one month from the initiation of antituberculosis treatment due to septic shock. Therefore, it is very important to evaluate the bacillary status before initiating any immunosuppressive treatment.


<div xmlns="http://www.w3.org/1999/xhtml">
<sec id="j_pneum-2023-0039_s_001">
<div>Introduction</div>
<p>Mycobacterium tuberculosis remains one of the major pathogens infecting approximately one-third of the population and is responsible for nearly 2 million deaths annually. It is known that rheumatological pathologies such as rheumatoid arthritis can be associated with an increased risk of association with tuberculosis, but it remains unknown what proportion of this risk comes from the immunologic disease itself and what proportion from immunosuppressive therapy. The latent form of tuberculosis can become active (about 10 per cent of the time) and a reactivated TB case can be fatal. Therefore, the patients with PAR should be screened for TB regularly. There are recommended test for TB like tuberculin skin test, interferon gamma release assay, sputum analysis and chest X-ray. (<a ref-type="bibr" href="#j_pneum-2023-0039_ref_001">1</a>) In the specialized literature, a lot of opportunistic and non-opportunistic infections are described in patients with PAR who follow treatment with the “anchor drugs” (methotrexate, azathioprine, cyclophosphamide, corticosteroids). An increased risk of developing active tuberculosis has been shown in patients with PAR receiving a mean prednisone dosage/day/year. With the introduction of biological therapy - inhibitors of TNFα in PAR, otherwise very effective, the development of tuberculosis was observed, TNFα representing a factor with a crucial role in the host’s immune response (<a ref-type="bibr" href="#j_pneum-2023-0039_ref_002">2</a>). The production of TNFα by alveolar macrophages is essential in tuberculous granuloma formation, cytokine production, leukocyte recruitment and destruction of pathogens, in this case Mycobacterium tuberculosis. Anti-TNFα agents proved to determine a good control of the symptoms and the lowering or arrest of the disease progression. However, it has been recognized that the anti- TNFα agents associate an increased risk of reactivation of latent tuberculosis infection (LTBI). A rare fatal presentation of mycobacterial infection, miliary TB, can occur in patients under immunosuppressive treatment especially when anti-TNFα agents are combine with other non-biological therapy (<a ref-type="bibr" href="#j_pneum-2023-0039_ref_003">3</a>).</p>
</sec>
<sec id="j_pneum-2023-0039_s_002">
<div>Case report</div>
<p>A 54 years old female, former smoker weaned for 15 years, with professional exposure, diagnosed in 2012 with rheumatoid arthritis, initially treated with Methotrexate and corticotherapy, then with Leflunomide and Adalimumab interrupted in June 2022 due to impaired renal function when she also performed in another medical center a CT scan (computed tomography) which highlighted multiple centrilobular “ground-glass” micronodules, disseminated in both lung areas, suggestive of pulmonary tuberculosis- miliary form (<a ref-type="fig" href="#j_pneum-2023-0039_fig_001">Figure 1</a>) has been admitted in our Institute for dyspnea at moderate-low exertion, cough with mucous sputum, loss of appetite, weight loss and fatigue. She was also known with hepatitis C and high blood pressure. In addition, in the other medical center, infective endocarditis was suspected following a prolonged febrile syndrome and an echocardiography with an image suggestive for vegetation on mitral valve, for which the patient has undergone antibiotic treatment with Vancomycin. We mention that we did not have medical documents to establish whether the patient underwent treatment for hepatitis C.</p>
<figure id="j_pneum-2023-0039_fig_001" position="float" fig-type="figure">
<h2>Figure 1.</h2>
<figCaption><p>Computed tomography: multiple centrilobular “ground-glass” micronodules, disseminated in both lung areas, suggestive of pulmonary tuberculosis-miliary form.</p></figCaption>
<img xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="graphic/j_pneum-2023-0039_fig_001.jpg" src="https://sciendo-parsed.s3.eu-central-1.amazonaws.com/662f97dadd1c3d1f87107d33/j_pneum-2023-0039_fig_001.jpg?X-Amz-Algorithm=AWS4-HMAC-SHA256&amp;X-Amz-Date=20240629T113214Z&amp;X-Amz-SignedHeaders=host&amp;X-Amz-Expires=18000&amp;X-Amz-Credential=AKIA6AP2G7AKP25APDM2%2F20240629%2Feu-central-1%2Fs3%2Faws4_request&amp;X-Amz-Signature=60645db42126eac306860f260aa45395a2e1f9e10e47b474971f1a0311e04077" class="mw-100"/>
</figure>
<sec id="j_pneum-2023-0039_s_002_s_001">
<div>On clinical examination, the following were observed</div>
<p>affected general condition, hemodynamically and respiratory stable, overweight, epigastric pain and right upper quadrant and vomiting.</p>
</sec>
<sec id="j_pneum-2023-0039_s_002_s_002">
<div>The paraclinical investigations</div>
<p>the results from blood sample highlight nitrogen retention syndrome (increased creatinine=2.55mg/dL), low estimated glomerular filtration rate (22mL/min/1.73m<sup>2</sup>), mild microcytic hypochromic anemia (Hb=11.7g/dL), hyposideremia and <italic>anti-HCV antibodies- positive</italic>.</p>
<p>The ECG tracing (electrocardiogram) showed sinus tachycardia and DI, aVL, V3-V6 T wave inversion. The transthoracic echocardiography showed signs of heart failure with moderate left ventricular systolic dysfunction, signs of ischemic heart disease, moderate mitral regurgitation and no direct or indirect signs of infective endocarditis were observed. Fibrobronchoscopy with bronchial aspirate was also performed for Mycobacterium tuberculosis bacteriology and GeneXpert test result was Mtb complex detected medium, drug-sensitive tuberculosis. Abdominal ultrasound showed an embedded stone in the gallbladder infundibulum.</p>
<p>The clinical and paraclinical investigations led to some diagnoses namely pulmonary tuberculosis-miliary form-Mtb complex detected medium, seropositive rheumatoid arthritis, high blood pressure, heart failure with moderate left ventricular systolic dysfunction, ischemic heart disease, moderate mitral regurgitation, hepatitis C was confirmed, cholelithiasis, chronic kidney disease and microcytic hypochromic anemia. <italic>The evolution</italic> was unfavorable, the patient did not tolerate the antituberculosis treatment for 3 weeks (Isoniazid-200mg, Rifampin-300mg, Pyrazinamide-1000mg, Ethambutol- 800mg) presenting multiple adverse reactions during hospitalization, including enterocolitis with Clostridium difficile and drug-induced toxic hepatitis (the highest values of transaminases (TGO=372U/L, TGP=803U/L), but they decreased after stopping antituberculosis treatment). For the enterocolitis with Clostridium Difficile, Vancomycin 2.5mL every 6 hours, oral administration and Metronidazole 500mg, 1 bottle every 12 hours have been used for 10 days. The anemic syndrome persisted for which the patient received three blood transfusions (the lowest value of hemoglobin was 7 g/dL, which increased to 11g/dL after red blood cell transfusion). She also contacted a urinary infection with Pseudomonas aeruginosa and Candida albicans which were treated according to the antibiogram with Levofloxacin 500mg, once a day, orally and Fluconazole 150mg, once a day orally, both for 5 days. (<a ref-type="fig" href="#j_pneum-2023-0039_fig_002">Figure 2</a>) But after 2 months from admission, the patient’s condition suddenly deteriorated with severe metabolic acidosis (pH=6.7) and hyperlactacidemia (lactic acid=7.7mmol/L), a fact that has concurred with the moment when a computer tomography was performed. Later, the result of the computer tomography revealed bilateral pleural effusion, more on the right side, which associated pulmonary consolidation that almost entirely involved the right lower lobe. Unfortunately, the patient subsequently suffered an unsustainable cardio-respiratory arrest and death.</p>
<figure id="j_pneum-2023-0039_fig_002" position="float" fig-type="figure">
<h2>Figure 2.</h2>
<figCaption><p>Antibiogram for Pseudomonas aeruginosa.</p></figCaption>
<img xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="graphic/j_pneum-2023-0039_fig_002.jpg" src="https://sciendo-parsed.s3.eu-central-1.amazonaws.com/662f97dadd1c3d1f87107d33/j_pneum-2023-0039_fig_002.jpg?X-Amz-Algorithm=AWS4-HMAC-SHA256&amp;X-Amz-Date=20240629T113214Z&amp;X-Amz-SignedHeaders=host&amp;X-Amz-Expires=18000&amp;X-Amz-Credential=AKIA6AP2G7AKP25APDM2%2F20240629%2Feu-central-1%2Fs3%2Faws4_request&amp;X-Amz-Signature=69ee3ba7c840fb6cd4275c4b68eb5bd5522832e48979363cb758cdc9329ed2b5" class="mw-100"/>
</figure>
</sec>
</sec>
<sec id="j_pneum-2023-0039_s_003">
<div>Discussions</div>
<p>Canadian researchers have shown through case-control studies a modestly increased risk of tuberculosis in patients receiving methotrexate and the rate of development of tuberculosis in people with rheumatologic pathology who are treated with either methotrexate or biological therapy is generally higher than in the general population. Other studies based on the development rate of tuberculosis in countries such as Spain, South Africa and Canada have shown that this rate is higher in patients who were prescribed methotrexate associated with corticosteroids or other immunosuppressants. The patient in the case report, at the initiation of treatment for rheumatoid arthritis received the combination with corticosteroids (<a ref-type="bibr" href="#j_pneum-2023-0039_ref_004">4</a>). Leflunomide can increase the susceptibility of tuberculosis reactivation, as it has an anti-inflammatory and immunomodulatory role. <italic>Hočevar et al</italic>. presents in “Leflunomide-associated tuberculosis?” 5 cases that developed tuberculosis during treatment with leflunomide. In 4 out of 5 cases, leflunomide was the only drug belonging to non-biological therapy (DMARDs- disease-modifying antirheumatic drugs), used at the time of symptomatology suggestive of tuberculosis and in 3 of the cases it was combined with corticosteroid therapy and in 1 case with methotrexate. In the case of patients who received the combination, the contribution of both drugs to the occurrence of tuberculosis cannot be excluded. Also, at the patient in the case report, methotrexate was replaced with leflunomide due to adverse gastrointestinal reactions, and when tuberculosis was diagnosed, she was treated with leflunomide (<a ref-type="bibr" href="#j_pneum-2023-0039_ref_005">5</a>). It is considered that any patient with rheumatoid arthritis should be tested for both latent tuberculosis infection and active disease, even if they are not receiving treatment with any DMARDs. This fact is recommended, because patients with rheumatoid arthritis have a 4 times higher risk of developing tuberculosis compared to the general population. Experts recommend tests for tuberculosis annually, which involves the patient’s medical history, Mantoux test, chest X-ray and objective clinical examination (<a ref-type="bibr" href="#j_pneum-2023-0039_ref_006">6</a>) (<a ref-type="bibr" href="#j_pneum-2023-0039_ref_007">7</a>). The presented patient who also received anti-TNFα treatment (Hyrimoz- adalimumab) was diagnosed with miliary pulmonary tuberculosis. This is considered a rare and at the same time fatal form of tuberculous infection that can occur in the presence of the host’s immunity under the prescription of immunosuppressive agents (<a ref-type="bibr" href="#j_pneum-2023-0039_ref_008">8</a>). In the literature, a series of cases of pulmonary tuberculosis have been documented in patients receiving anti-TNFα therapy, such as etanercept, infliximab and adalimumab. The risk proved to be higher in the case of infliximab and adalimumab compared to etanercept. It is considered a fact that most cases are due to the reactivation of latent tuberculosis infection and several studies have demonstrated that pevention of latent tuberculosis infection before or during anti-TNFα therapy reduces the risk of reactivation, but also the risk of critical forms of active tuberculosis (<a ref-type="bibr" href="#j_pneum-2023-0039_ref_009">9</a>).</p>
<sec id="j_pneum-2023-0039_s_003_s_001">
<div>Case particularity</div>
<p>The patient presented above has had an unfavorable evolution despite the treatment administered, a fact supported by the data mentioned in the discussions. She was in biological treatment for PAR with Adalimumab, a context that greatly contributed to the risk of developing tuberculosis. In addition, the miliary form of tuberculosis determined the unfavorable evolution too (<a ref-type="bibr" href="#j_pneum-2023-0039_ref_010">10</a>).</p>
</sec>
</sec>
<sec id="j_pneum-2023-0039_s_004">
<div>Conclusions</div>
<p>In conclusion, pulmonary tuberculosis associated with rheumatoid arthritis can present atypical manifestations that can lead to an incorrect or delayed diagnosis with unfavorable evolution. Thus, it is very important to evaluate the bacillary status before initiating any immunosuppressive treatment.</p>
</sec>
</div>

Combination with reserved prognosis: TB- rheumatoid arthritis

Pneumologia

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Asociere cu prognostic rezervat: TB-poliartrita reumatoida

As shown in a Spanish study, patients with rheumatoid arthritis (PAR) have a 4-fold increased risk of developing TB (tuberculosis) compared to the general...

Combination with reserved prognosis: TB- rheumatoid arthritis

Article Category: Case Report

Data publikacji: 02 maj 2024

Zakres stron: 150 - 153

DOI: https://doi.org/10.2478/pneum-2023-0039

Słowa kluczowe
tuberculosis, rheumatoid arthritis, immunosuppressive treatment

© 2022 Simona Roșu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1.

Figure 2.

Combination with reserved prognosis: TB- rheumatoid arthritis

Article Category: Case Report

Data publikacji: 02 maj 2024

Zakres stron: 150 - 153

DOI: https://doi.org/10.2478/pneum-2023-0039

Słowa kluczowetuberculosis, rheumatoid arthritis, immunosuppressive treatment

© 2022 Simona Roșu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1.

Figure 2.

Słowa kluczowe
tuberculosis, rheumatoid arthritis, immunosuppressive treatment